TNF and inflammatory bowel disease: Phase III GEMINI trials have demonstrated efficacy of vedolizumab in the induction and maintenance of both UC and CD.93,94 Patients with anti-TNF-responsive SpA but poorly controlled IBD may benefit from the addition of vedolizumab for their luminal disease.